{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:29:59Z","timestamp":1793813399073,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018046","name":"Nippon Kayaku Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jhepr.2026.102002","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:33:02Z","timestamp":1787985182000},"page":"102002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atezolizumab\u2013bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-0842","authenticated-orcid":false,"given":"Yasuto","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Sue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7283-3517","authenticated-orcid":false,"given":"Hideki","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Kawanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-0008","authenticated-orcid":false,"given":"Kazuhiro","family":"Nouso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3996-7502","authenticated-orcid":false,"given":"Kazuya","family":"Kariyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yasunaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kuwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Toshimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Iwado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3380-6460","authenticated-orcid":false,"given":"Akio","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takabatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-285X","authenticated-orcid":false,"given":"Takeshi","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Shimose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-2881","authenticated-orcid":false,"given":"Motoyuki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.102002_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.929141","article-title":"Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma","volume":"13","author":"Xin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.102002_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1474442","article-title":"Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience","volume":"15","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102002_bib3","first-page":"571","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: a randomized trial","volume":"64","author":"Ikeda","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102002_bib4","first-page":"1","article-title":"Hepatic arterial infusion chemotherapy with cisplatin plus sorafenib vs. sorafenib alone in advanced hepatocellular carcinoma: a randomized trial","volume":"94","author":"Kudo","year":"2018","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.jhepr.2026.102002_bib5","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102002_bib6","first-page":"336","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis in immune checkpoint inhibitor responses","volume":"15","author":"Hegde","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102002_bib7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/livers4040042","article-title":"Abscopal effect with liver-directed therapy: a review of the current literature and future directions","volume":"4","author":"Levine","year":"2024","journal-title":"Livers"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102002_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102002_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Conde. Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jhepr.2026.102002_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"REDCap Consortium, the REDCap consortium: building an international community of software partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102002_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102002_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"20","key":"10.1016\/j.jhepr.2026.102002_bib13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jhepr.2026.102002_bib14","first-page":"6079","article-title":"Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: results from the IMbrave150 trial","volume":"10","author":"Salem","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102002_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","article-title":"Immunogenicity of cell death and cancer immunotherapy","volume":"22","author":"Catanzaro","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhepr.2026.102002_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.728018","article-title":"From immunogenic cell death to immunogenic modulation: select chemotherapy regimens induce a spectrum of immune enhancing activities in the tumor microenvironment","volume":"11","author":"Fabian","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2026.102002_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1390263","article-title":"Emerging role of immunogenic cell death in cancer immunotherapy","volume":"15","author":"Arimoto","year":"2024","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102002_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188946","article-title":"Reinforcing the immunogenic cell death to enhance cancer immunotherapy","volume":"1878","author":"Yu","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.jhepr.2026.102002_bib19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"issue":"14","key":"10.1016\/j.jhepr.2026.102002_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411434","article-title":"Friend or Foe? Locoregional therapies and immunotherapies in the current hepatocellular treatment landscape","volume":"24","author":"Young","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jhepr.2026.102002_bib21","doi-asserted-by":"crossref","first-page":"8598","DOI":"10.3390\/ijms24108598","article-title":"The synergistic effect of interventional locoregional treatments and immunotherapy for the treatment of hepatocellular carcinoma","volume":"24","author":"Brandi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.jhepr.2026.102002_bib22","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jhepr.2026.102002_bib23","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins (Basel)"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102002_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"10.1016\/j.jhepr.2026.102002_bib25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jhepr.2026.102002_bib26","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"10103","key":"10.1016\/j.jhepr.2026.102002_bib27","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 2 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102002_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102002_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2011.01.028","article-title":"Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis","volume":"74","author":"Botrel","year":"2011","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102002_bib30","first-page":"917","article-title":"Clinical pharmacology of intraarterial cis-diamminedichloroplatinum (II)","volume":"43","author":"Stewart","year":"1983","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102002_bib31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ijc.2910600507","article-title":"Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies","volume":"60","author":"Vexler","year":"1995","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102002_bib32","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jhep.2019.01.028","article-title":"Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival","volume":"70","author":"Llovet","year":"2019","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:42:05Z","timestamp":1793810525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2589555926002739"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102002","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atezolizumab\u2013bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102002"}}